SCHEMBL7538215

SCHEMBL7538215

CCCCCCNC(=O)c1ccc(C(C)C)cc1

nearest known ligand 0.69

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.69
NAAA Q02083 2/20 0.67
HPGD P15428 1/20 0.67
EPHX1 P07099 1/20 0.65
SMN1; SMN2 Q16637 4/20 0.63
RAB9A P51151 4/20 0.63
NPC1 O15118 3/20 0.63
LMNA P02545 1/20 0.63
MLYCD O95822 1/20 0.62
CA2 P00918 1/20 0.61
THRA P10827 1/20 0.58
THRB P10828 1/20 0.58
HDAC3 O15379 1/20 0.57
MEN1 O00255 2/20 0.57
KMT2A Q03164 2/20 0.57
ALDH1A1 P00352 1/20 0.57
MAPT P10636 1/20 0.57
FOLH1 Q04609 2/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13577935 0.98 HPGD (0.68) L3MBTL1NAAAHPGDEPHX1SMN1; SMN2
SCHEMBL104793 0.94 HPGD (0.70) L3MBTL1NAAAHPGDEPHX1SMN1; SMN2
SCHEMBL30527282 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL10481026 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL258708 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL845966 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL6535660 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL9265536 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL9504178 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1
SCHEMBL846047 0.88 L3MBTL1 (0.86) L3MBTL1NAAASMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130259882-A1 Conjugate of Folate and Antibody Preparation Method and Use Thereof ZHEJIANG JIANFENG HANSHENG BIOSCIENCES CO., LTD. (CN) 2013-10-03 US disclosed
US-20130259882-A1 Conjugate of Folate and Antibody Preparation Method and Use Thereof ZHEJIANG JIANFENG HANSHENG BIOSCIENCES CO., LTD. (CN) 2013-10-03 US disclosed
WO-2012062094-A1 CONJUGATE OF FOLATE AND ANTIBODY, PREPARATION METHOD AND USE THEREOF 武汉华耀生物医药有限公司 (CN) 2012-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259882-A1 Conjugate of Folate and Antibody Preparation Method and Use Thereof FOLR1, FOLR2, DHFR L3MBTL1 3734/4885NAAA 547/4885HPGD 155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.